Search results for "Digest"

showing 10 items of 3038 documents

HCV infection and oral lichen planus: a weak association when HCV is endemic.

2004

Oral lichen planus (OLP), an immune-mediated disorder, has been reported as an extra-hepatic manifestation of Hepatitis C virus (HCV) infection, especially in HCV hyperendemic areas such as southern Europe and Japan. The aim of this study was to investigate from an epidemiological standpoint whether HCV infection is an important factor affecting the relative risk of OLP in a Mediterranean population or whether this relates to the degree of HCV endemicity. Two cohorts of OLP patients resident in two different regions of southern Italy (Campania and Sicily; n = 859) were evaluated for HCV infection status and categorized into five age classes to respective region-matched controls. No signific…

AdultMalemedicine.medical_specialtyEpidemiology of HCV infectionEndemic DiseasesHepatitis C virusPopulationHepacivirusBiologymedicine.disease_causestomatognathic systemVirologyEpidemiologyPrevalencemedicineHumanseducationeducation.field_of_studyHepatologySignificant differencevirus diseasesHepatitis C AntibodiesMiddle Agedmedicine.diseaseHepatitis Cdigestive system diseasesstomatognathic diseasesInfectious DiseasesItalyRelative riskImmunologyOral lichen planusEtiologyWeak associationFemaleOral lichen planusHepatitis C viruLichen Planus Oral
researchProduct

Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and b…

2004

The increasing use of endoscopic resection for curative treatment of early oesophageal cancers requires accurate staging before therapy. In a prospective blinded trial, we compared staging of early oesophageal carcinoma using high resolution endoscopy (HR-E) with staging using high resolution endosonography (HR-EUS).A total of 100 patients (89 men, 11 women; mean age 63.9 (10.8) years (range 31-91)) with a suspicion of early oesophageal adenocarcinoma (n = 81) or squamous cell carcinoma (n = 19) were enrolled in the study. After endoscopic staging with high resolution video endoscopy by two experienced endoscopists, HR-EUS was performed by an experienced endosonographer who was blinded to t…

AdultMalemedicine.medical_specialtyEsophageal NeoplasmsHigh resolutionAdenocarcinomaEndosonographySubmucosamedicineCarcinomaHumansSingle-Blind MethodProspective StudiesEsophagusProspective cohort studyAgedNeoplasm StagingAged 80 and overmedicine.diagnostic_testbusiness.industryGastroenterologyReproducibility of ResultsCancerMiddle Agedmedicine.diseasedigestive system diseasesSurgeryEndoscopyOesophagusmedicine.anatomical_structureCarcinoma Squamous CellAdenocarcinomaFemaleEsophagoscopyRadiologybusinessGut
researchProduct

Carcinoma of the hypopharynx and the cervical oesophagus: a surgical challenge.

1999

To report our results after reconstruction of the upper digestive tract for locally advanced carcinoma of the hypopharynx and cervical oesophagus.Open study.Teaching University hospital, Germany.Of the 517 patients who presented with carcinoma of the oesophagus between September 1985 and March 1997, 16 had a locally advanced tumour of the hypopharynx and 25 of the cervical oesophagus.Free jejunal grafts were used after circular resection in all patients with carcinoma of the hypopharynx, and for the 3 with oesophageal carcinoma in whom we obtained adequate resection margins. In the remainder stomach was used in 21 and colon in 1.Morbidity and mortality.After jejunal grafting 1 patient died …

AdultMalemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentAnastomosisAdenocarcinomaEsophagusPostoperative ComplicationsHypopharyngeal Neoplasmotorhinolaryngologic diseasesmedicineCarcinomaHumansHospital MortalityEsophagusSurvival rateNeoplasm StagingHypopharyngeal Neoplasmsbusiness.industryStomachdigestive oral and skin physiologyMiddle Agedmedicine.diseaseSurgeryEsophagectomySurvival RateHypopharynxmedicine.anatomical_structureJejunumEsophagectomyCarcinoma Squamous CellAdenocarcinomaSurgeryFemalebusinessThe European journal of surgery = Acta chirurgica
researchProduct

Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease.

2009

Introduction: Functional dyspepsia and non-erosive reflux disease (NERD) are prevalent gastrointestinal conditions with accumulating evidence regarding an overlap between the two. Still, patients with NERD represent a very heterogeneous group and limited data on dyspeptic symptoms in various subgroups of NERD are available. Aim: To evaluate the prevalence of dyspeptic symptoms in patients with NERD subclassified by using 24 h impedance-pH monitoring (MII-pH). Methods: Patients with typical reflux symptoms and normal endoscopy underwent impedance-pH monitoring off proton pump inhibitor treatment. Oesophageal acid exposure time (AET), type of acid and non-acid reflux episodes, and symptom ass…

AdultMalemedicine.medical_specialtyEsophageal pH MonitoringAdolescentNerdmedicine.drug_classProton-pump inhibitorGastroenterologyBody Mass IndexDiagnosis DifferentialYoung AdultEsophagusSex FactorsHeartburnInternal medicinemedicineElectric ImpedanceHumansNERD FD FH SAP1506EsophagusDyspepsiaAgedAnalysis of Variancemedicine.diagnostic_testbusiness.industryEsophageal diseaseStomachdigestive oral and skin physiologyStomachGastroenterologyRefluxHeartburnMiddle Agedmedicine.diseasedigestive system diseasesOesophagusmedicine.anatomical_structureGastroesophageal RefluxFemaleEsophagoscopymedicine.symptombusinessEsophageal pH monitoring
researchProduct

Reduction of negative alliesthesia for sweet gustatory stimuli by cyproheptadine, a serotonin antagonist

1990

Cyproheptadine (CH) is a serotonin antagonist that increases food intake and body weight. In order to elucidate its mechanism of action on the control of food intake, hunger ratings, pleasure-displeasure to sweet gustatory stimuli and negative alliesthesia induced by a 50 g glucose load were compared in 14 healthy subjects after they had received a placebo or 16 mg of CH. Cyproheptadine did not affect the hunger rating, nor the affective rating in fasted subjects, but it reduced significantly the negative alimentary alliesthesia induced by the glucose load. It was concluded that CH increases food intake more by reducing satiation than by increasing hunger. This is in line with the anti-sero…

AdultMalemedicine.medical_specialtyFood intakeCyproheptadineSatiationAlliesthesiaCyproheptadinePlaceboSatiety ResponseGeneral Biochemistry Genetics and Molecular BiologyEatingRandom AllocationInternal medicinemedicineHumansGeneral Pharmacology Toxicology and PharmaceuticsAnalysis of VarianceMotivationbusiness.industrydigestive oral and skin physiologyAntagonistHealthy subjectsGeneral MedicineMiddle AgedGlucoseEndocrinologyMechanism of actionTasteFemaleSerotoninmedicine.symptombusinessmedicine.drugLife Sciences
researchProduct

Outcome of esophageal function and 24-hour esophageal pH monitoring after vertical banded gastroplasty and Roux-en-Y gastric bypass.

2004

Background: One of the co-morbidities frequently associated with morbid obesity is gastro-esophageal reflux disease (GERD), present in >50 % of morbidly obese individuals. We compared the anti-reflux effect of vertical banded gastroplasty (VBG) and Roux-en-Y gastric bypass (RYGBP), and their effect on esophageal function. Methods: 10 patients underwent VBG and 40 patients underwent RYGBP. Anthropometric parameters, symptomatology of GERD, esophageal manometry (EM), isotopic esophageal emptying (IEE) and 24hr esophageal pH monitoring were recorded in all patients preoperatively, and at 3 months and 1 year postoperatively. Results: Preoperatively, there was a high prevalence of GERD, symptoma…

AdultMalemedicine.medical_specialtyGastroplastyEndocrinology Diabetes and MetabolismGastric BypassAnastomosisGastroenterologyEsophagusWeight lossInternal medicinemedicineHumansProspective StudiesProspective cohort studyNutrition and Dieteticsmedicine.diagnostic_testbusiness.industryRefluxAnastomosis Roux-en-YHydrogen-Ion Concentrationmedicine.diseaseRoux-en-Y anastomosisDysphagiadigestive system diseasesSurgeryObesity MorbidDiagnostic Techniques Digestive SystemTreatment OutcomeGERDGastroesophageal RefluxSurgeryFemalemedicine.symptomEsophageal pH monitoringbusinessObesity surgery
researchProduct

Is Routine Preoperative Upper Endoscopy in Gastric Banding Patients Really Necessary?

2006

Background: Preoperative evaluation for bariatric surgery is complex. Our investigation focused on the necessity for upper gastrointestinal (GI) endoscopy as a routine procedure before performing gastric banding. Methods: A consecutive series of 145 patients underwent laparoscopic adjustable gastric banding (LAGB). Gastroscopy was performed routinely before LAGB. All patients were interviewed before gastroscopy regarding gastroesophageal symptoms. Gastroscopic findings and the results of the interview were blinded and set in comparison. Furthermore, we analyzed whether upper GI symptoms, BMI, age or gender were predictive parameters for pathological findings on gastroscopy. Small hiatal her…

AdultMalemedicine.medical_specialtyGastroplastyGastric bandingEndocrinology Diabetes and MetabolismGastroenterologyHiatal herniaInternal medicinePreoperative CaremedicineHumansMedical historyEndoscopy Digestive SystemPathologicalNutrition and Dieteticsmedicine.diagnostic_testDiagnostic Tests Routinebusiness.industryMiddle Agedmedicine.diseasedigestive system diseasesObesity MorbidEndoscopySurgeryGastric PolypFemaleSurgeryAbnormalitybusinessEsophagitisObesity Surgery
researchProduct

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

2004

We assessed the effectiveness and safety of an induction dose of peginterferon alfa-2b (PEG-IFN) plus ribavirin for initial treatment of patients with genotype 1 chronic HCV infection in a randomized, controlled, multicenter trial.Three hundred and eleven naïve patients infected with genotype 1 and chronic hepatitis were randomly assigned to 48-week treatment with PEG-IFN once weekly (80-100 micrograms depending on body weight for 8 weeks, followed by 50 micrograms for the next 40 weeks), or standard interferon alfa-2b (IFN) 6 million units on alternate days, both in combination with ribavirin (1000-1200 mg/day).PEG-IFN plus ribavirin significantly increased sustained virological response (…

AdultMalemedicine.medical_specialtyGenotypeCombination therapyFibrosiHepacivirusAlpha interferonHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyPolyethylene Glycolslaw.inventionchemistry.chemical_compoundRandomized controlled triallawMulticenter trialInternal medicineRibavirinmedicineHumansCombination therapyHepatologybiologybusiness.industryRibavirinfibrosisInterferon-alphavirus diseasesDrug ToleranceHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseRecombinant Proteinsdigestive system diseasesMulticenter trial; Combination therapy; fibrosischemistryMulticenter trialImmunologyPeginterferon alfa-2bFemaleSafetybusinessmedicine.drugJournal of Hepatology
researchProduct

Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin

2008

Guidelines for the treatment of patients infected with hepatitis C virus of genotypes 2 and 3 (HCV-2 and HCV-3, respectively) recommend a 24-week course of Peg-interferon (Peg-IFN) alpha-2a combined with ribavirin, despite 50% of patients in registration trials attaining a sustained virologic response (SVR) following Peg-IFN alpha-2a monotherapy. The aim of this study was to delineate patient characteristics that might help to identify individuals likely to benefit from ribavirin discontinuation. One hundred and forty-four HCV-2- and HCV-3-infected patients initiated Peg-IFN alpha-2a (180 microg/week) and ribavirin (1000 or 1200 mg/day); those with viral clearance at week 4 were randomized …

AdultMalemedicine.medical_specialtyGenotypeCombination therapyHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeChronic hepatitis CAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundVirologyInternal medicineRibavirinmedicineHumansRapid Virologic ResponseHepatologyPeg-interferonbusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis CMiddle AgedViral Loadmedicine.diseaseHepatitis CRecombinant Proteinsdigestive system diseasesDiscontinuationClinical trialTreatment OutcomeInfectious DiseasesWithholding TreatmentchemistryImmunologyChronic hepatitis C; Clinical trial; Peg-interferon; Ribavirin;FemaleViral hepatitisbusinessViral load
researchProduct

Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial

2008

It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48-week treatment. Patients (n_696) received peginterferon alfa-2a, 180 mg/week, or peginterferon alfa-2b, 1.5 mg/kg/week, plus ribavirin, 1000-1200 mg/day, for 48 weeks (standard, n _237) or for 24, 48, or 72 weeks if HCV-RNA–negative at weeks 4, 8, or 12, respectively (variable, n _ 459). Sustained virologic response (SVR) was achieved in 45.1% [95% confidence interval (CI) 38.8-51.4] of the patients in the standard group and in 48.8% (CI 44.2-53.3) of the patients in the variable group (P _ 0.37). The percentages of …

AdultMalemedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicineRibavirinmedicineHumansProspective StudiesRapid Virologic Responsegenotype 1Hepatologybusiness.industryRibavirinStandard treatmentInterferon-alphavirus diseasesHepatitis CMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesConfidence intervalSurgeryTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalehepatitis Cbusiness
researchProduct